Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-25 @ 1:06 AM
NCT ID:
NCT06612593
Eligibility Criteria:
Inclusion Criteria:
* -Adult patients.
* Both males and females will be included
* Diagnosed Parkinson's disease according to the MDS criteria 2015
* At least 5 years of disease duration
* On stable Levodopa\\carbidopa regimen for the past 6 months.
* Clinically diagnosed with dyskinesia
Exclusion Criteria:
* -Secondary causes of Parkinsonism
* Atypical parkinsonian syndromes
* Active malignancy
* Known intolerance or hypersensitivity to cilostazol
* Participation in other interventional trials
* Patients with hepatic (AST and ALT more than 3 times the upper normal limit) or renal impairment (eGFR less than 60 ml\\min).
* Patients receiving warfarin, other anti-coagulants or anti-platelet therapy.
* Patients with Congestive heart failure.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT06612593
Study Brief:
Protocol Section:
NCT06612593